Liquidia Corp
Close on Oct 19, 2026
- Market cap
- $3.46B
- P/E (TTM)
- 24.6
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | $171.68M | $0.74 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | Before market open | $132.87M | $0.52 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | $92.02M | $0.15 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | Before market open | $54.34M | $-0.04 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $3.10M | $-0.45 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 19, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | $4.40M | $-0.30 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | $3.70M | $-0.37 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 13, 2024 | Before market open | – | – | – |
Press releases
Announcements Liquidia filed with the SEC
Liquidia Announces Global Settlement Resolving All Pending Litigation
Material agreement · Agreement terminated · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Liquidia Provides Update on Hatch-Waxman
Other events · EX-99.1 to Form 8-K
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment
Other events · EX-99.1 to Form 8-K
Liquidia Corporation Reports Second Quarter
Results of operations · Other events · EX-99.1 to Form 8-K
©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED
Results of operations · Other events · EX-99.2 to Form 8-K
in the S&P SmallCap 600® Index
Other events · EX-99.1 to Form 8-K
Liquidia Corporation Reports First Quarter
Results of operations · Other events · EX-99.1 to Form 8-K
©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED First Quarter 2026 Earnings & Corporate Update Liquidia Corporation May 11, 2026
Results of operations · Other events · EX-99.2 to Form 8-K
Liquidia Corporation Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Full-Year 2025 YUTREPIA Net Sales and Corporate Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Liquidia Corporation Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Liquidia Corporation Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Million from Healthcare Royalty (HCRx) Following
Other events · EX-99.1 to Form 8-K
YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
Other events · EX-99.1 to Form 8-K
YUTREPIA™ (treprostinil) Inhalation Powder for
Other events · EX-99.1 to Form 8-K
Liquidia Corporation Provides Update on Litigation Filed by United
Other events · EX-99.1 to Form 8-K
Corporation Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
84683063 68629575 http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember http://fasb.org/us-gaap/2024#MeasurementInputDiscountRateMember 0.00 http://liquidia.com/20241231#OperatingAndFinanceLeaseLiabilityCurrent http://liquidia.com/20241231#OperatingAndFinanceLeaseLiabili…
Other events · EX-99.1 to Form 8-K
District Court Dismisses Dispute Filed by United Therapeutics Against
Other events · EX-99.1 to Form 8-K
Liquidia Corporation Announces FDA Acceptance
Other events · EX-99.1 to Form 8-K
Reports Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million
Material agreement · Other events · EX-99.1 to Form 8-K
Corporation Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
United States Supreme Court Declines to
Other events · EX-99.1 to Form 8-K
Biopharm Expand Collaboration to Develop
Material agreement · Other events · EX-99.1 to Form 8-K
Liquidia Corporation Announces Raise of $67.5
Material agreement · Other events · EX-99.1 to Form 8-K
Liquidia Files Litigation to Challenge
Other events · EX-99.1 to Form 8-K
U.S. FDA Grants Tentative Approval of YUTREPIA™
Other events · EX-99.1 to Form 8-K
Corporation Reports Second Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
Other events · EX-99.1 to Form 8-K
Reports First Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
Other events · EX-99.1 to Form 8-K
Liquidia Corporation Reports Full Year
Results of operations · EX-99.1 to Form 8-K
Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
Other events · EX-99.1 to Form 8-K
N.C., January 19, 2024 – Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced
Executive or director change · Other events · EX-99.1 to Form 8-K
Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
Unregistered share sale · Other events · EX-99.1 to Form 8-K
Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
Unregistered share sale · Other events · EX-99.2 to Form 8-K
Liquidia Corporation Announces $100 Million
Material agreement · Other events · EX-99.1 to Form 8-K
U.S. Federal Circuit Affirms Earlier PTAB
Other events · EX-99.1 to Form 8-K
Pricing of Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K